Ifosfamide

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

EMLc | Codes ATC: L01AA06

Indication	Ewing sarcoma of bone or articular cartilage of unspecified sites Code ICD11: 2B52.Z
INN	Ifosfamide
Type de médicament	Chemical agent
Type de liste	Liste complémentaire
Formulations	**Parenteral > General injections > IV:** 500 mg in vial powder for injection ; 1 g in vial powder for injection ; 2 g in vial powder for injection
Historique des statuts LME	Ajouté pour la première fois en 2009 (TRS 958) Modifié en 2015 (TRS 994)
Sexe	Tous
Âge	Aussi recommandé pour les enfants
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets.
Balises	Cancer
Wikipédia	Ifosfamide
DrugBank	Ifosfamide

Résumé des preuves et recommandation du comité d'experts

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for ifosfamide on the complementary list of the EML for use in treatment protocols for Ewing sarcoma was specifically endorsed. Additionally, ifosfamide was added on the complementary list of the EMLc for this indication. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for Ewing sarcoma is attached.